Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.51 |
| ▸ | MTHFD1 | P11586 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | DHFR | P00374 | 4/20 | 0.51 |
| ▸ | TYMS | P04818 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.49 |
| ▸ | FPGS | Q05932 | 2/20 | 0.48 |
| ▸ | MTHFD2 | P13995 | 3/20 | 0.47 |
| ▸ | ATIC | P31939 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2166341 | 0.93 | MTHFD1 (0.63) | MTHFD1DHFRTYMSKDM4EMEN1 | |
| SCHEMBL17097094 | 0.93 | MTHFD1 (0.63) | MTHFD1DHFRTYMSKDM4EMEN1 | |
| Glutathione SCHEMBL16097636 | 0.87 | MTHFD1 (0.45) | MTHFD1LMNADHFRTYMSKDM4E | |
| SCHEMBL26045339 | 0.82 | TYMS (0.55) | MTHFD1DHFRTYMSKDM4EMEN1 | |
| Levomefolic Acid SCHEMBL29979430 | 0.79 | MTHFD1 (0.75) | MTHFD1LMNADHFRTYMSSOST | |
| Levomefolic Acid SCHEMBL692440 | 0.79 | MTHFD1 (0.75) | MTHFD1LMNADHFRTYMSSOST | |
| Levomefolic Acid SCHEMBL29506219 | 0.79 | MTHFD1 (0.75) | MTHFD1LMNADHFRTYMSSOST | |
| Levomefolic Acid SCHEMBL1883636 | 0.79 | MTHFD1 (0.75) | MTHFD1LMNADHFRTYMSSOST | |
| Levomefolic Acid SCHEMBL30733832 | 0.79 | MTHFD1 (0.75) | MTHFD1LMNADHFRTYMSSOST | |
| Levomefolic Acid SCHEMBL9487492 | 0.79 | MTHFD1 (0.74) | MTHFD1LMNADHFRTYMSSOST |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160045440-A1 | FORMULATION OF AMORPHOUS CALCIUM L-5-METHYLTETRAHYDROFOLATE (L-5-MTHF-Ca) | CHEMO RESEARCH, S.L. (ES) | 2016-02-18 | — | — | US | claimed |
| EP-2976066-A1 | FORMULATION OF AMORPHOUS CALCIUM L-5-METHYLTETRAHYDROFOLATE (L-5-MTHF-Ca) | Chemo Research, S.L. (ES) | 2016-01-27 | — | — | EP | claimed |
| WO-2014146975-A1 | FORMULATION OF AMORPHOUS CALCIUM L-5-METHYLTETRAHYDROFOLATE (L-5-MTHF-Ca) | CHEMO RESEARCH, S.L. (ES) | 2014-09-25 | — | — | WO | claimed |
| EP-2781214-A1 | Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca) | Chemo Research, S.L. (ES) | 2014-09-24 | — | — | EP | claimed |
| WO-2024003061-A1 | COMPOSITION FOR THE TREATMENT OF THE HUMAN PAPILLOMAVIRUS INFECTION (HPV) | LO.LI. PHARMA S.R.L. (IT) | 2024-01-04 | — | — | WO | disclosed |
| US-20230181475-A1 | COMPOSITION COMPRISING METHYLFOLATE | ALFASIGMA S.P.A. (IT) | 2023-06-15 | — | — | US | disclosed |
| EP-4149437-A1 | COMPOSITION COMPRISING METHYLFOLATE | Alfasigma S.p.A. (IT) | 2023-03-22 | — | — | EP | disclosed |
| CN-115605188-A | Compositions comprising methylfolic acid | 阿尔法西格玛有限公司（IT） | 2023-01-13 | — | — | CN | disclosed |
| WO-2021228788-A1 | COMPOSITION COMPRISING METHYLFOLATE | ALFASIGMA S.P.A. (IT) | 2021-11-18 | — | — | WO | disclosed |
| US-20160271155-A1 | Vitamin Formulations | NESTEC SA (CH) | 2016-09-22 | — | — | US | disclosed |
| US-20160045440-A1 | FORMULATION OF AMORPHOUS CALCIUM L-5-METHYLTETRAHYDROFOLATE (L-5-MTHF-Ca) | CHEMO RESEARCH, S.L. (ES) | 2016-02-18 | — | — | US | disclosed |
| US-20160045440-A1 | FORMULATION OF AMORPHOUS CALCIUM L-5-METHYLTETRAHYDROFOLATE (L-5-MTHF-Ca) | CHEMO RESEARCH, S.L. (ES) | 2016-02-18 | — | — | US | disclosed |
| EP-2976066-A1 | FORMULATION OF AMORPHOUS CALCIUM L-5-METHYLTETRAHYDROFOLATE (L-5-MTHF-Ca) | Chemo Research, S.L. (ES) | 2016-01-27 | — | — | EP | disclosed |
| EP-2976066-A1 | FORMULATION OF AMORPHOUS CALCIUM L-5-METHYLTETRAHYDROFOLATE (L-5-MTHF-Ca) | Chemo Research, S.L. (ES) | 2016-01-27 | — | — | EP | disclosed |
| WO-2015077509-A1 | VITAMIN FORMULATIONS | NESTEC S.A. (CH) | 2015-05-28 | — | — | WO | disclosed |
| WO-2014146975-A1 | FORMULATION OF AMORPHOUS CALCIUM L-5-METHYLTETRAHYDROFOLATE (L-5-MTHF-Ca) | CHEMO RESEARCH, S.L. (ES) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014146975-A1 | FORMULATION OF AMORPHOUS CALCIUM L-5-METHYLTETRAHYDROFOLATE (L-5-MTHF-Ca) | CHEMO RESEARCH, S.L. (ES) | 2014-09-25 | — | — | WO | disclosed |
| EP-2781214-A1 | Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca) | Chemo Research, S.L. (ES) | 2014-09-24 | — | — | EP | disclosed |
| EP-2781214-A1 | Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca) | Chemo Research, S.L. (ES) | 2014-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271155-A1 | Vitamin Formulations | CYP24A1, VDR, CYP2R1 | PTGS2 1166/4885MTHFD1 683/4885LMNA 1479/4885 |
| US-20160045440-A1 | FORMULATION OF AMORPHOUS CALCIUM L-5-METHYLTETRAHYDROFOLATE (L-5-MTHF-Ca) | MTHFD1, MTHFD2, DHFR | PTGS2 1587/4885MTHFD1 1/4885LMNA 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.